MedTrace Logo

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma

NCT07746687 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2026-08-05

No results posted yet for this study

Summary

The purpose of this study is to assess how well JNJ-95597528 works when compared to placebo in adult participants with moderate to severe asthma (long-term condition that affects the airways in your lungs).

Conditions

Interventions

DRUG

JNJ-95597528

JNJ-95597528 will be administered as subcutaneous (SC) injection.

DRUG

Placebo

Placebo will be administered as SC injection.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-23
Primary Completion
2029-09-11
Completion
2030-07-04
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07746687 on ClinicalTrials.gov